Business Context and Reporting Period
This Form 8-K Current Report was filed by Natera, Inc. on April 19, 2023. The filing discloses a Second Amendment to the Employment Agreement with Matthew Rabinowitz, Ph.D., the Company's Executive Chairman and Co-Founder.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation terms.
- Base Salary: $400,000 per year through fiscal 2024.
- Annual Cash Bonus: Eligible for up to 85% of base salary for fiscal 2023 and 2024, contingent on performance goals.
- Equity Awards: Annual awards for fiscal 2023 and 2024 valued at 80% of the CEO's annual equity award value.
Material Changes Versus Prior Period
The Amendment modifies the terms of the employment agreement previously amended on May 9, 2021. Key changes include:
- Term Extension: Dr. Rabinowitz's service as Executive Chairman is extended through January 31, 2025.
- Severance Modification: The right to single-trigger accelerated vesting upon a change in control has been removed.
- Definition Updates: The definition of "good reason" has been revised.
Outlook, Risks, and Contingencies
The filing outlines specific contingencies regarding Dr. Rabinowitz's role and compensation beyond January 31, 2025:
- Role Transition: If the parties mutually agree to transition his role to solely Chairman of the Board after January 31, 2025, he will not be entitled to severance benefits.
- Enhanced Severance: If the Board elects not to extend an offer for him to serve as Chairman of the Board after January 31, 2025, and no agreement is reached, 100% of his unvested time- and performance-based equity awards will be accelerated.
- Future Filing: The full text of the Amendment is intended to be filed as an exhibit to the Form 10-Q for the quarter ending June 30, 2023.
Investor Verification Checklist
- Verify the specific performance goals established by the Board for the 85% cash bonus.
- Confirm the valuation of the CEO's equity awards to calculate the exact value of Dr. Rabinowitz's 80% equity allocation.
- Review the full text of the Amendment (Exhibit 10.1 and 10.2) for the revised definition of "good reason" and "change in control."
- Monitor the upcoming Form 10-Q for the quarter ending June 30, 2023, for the complete agreement text.